ZNF683 (Hobit) Marks a CD8+ T Cell Population Associated with Anti-Tumor Immunity Following Anti-PD-1 Therapy for Richter Syndrome - Role of intra-Clonal HEterogeneity and Leukemic environment in ThErapy Resistance of chronic leukemias Accéder directement au contenu
Article Dans Une Revue Blood Année : 2022

ZNF683 (Hobit) Marks a CD8+ T Cell Population Associated with Anti-Tumor Immunity Following Anti-PD-1 Therapy for Richter Syndrome

Dates et versions

hal-03950370 , version 1 (21-01-2023)

Identifiants

Citer

Camilla Lemvigh, Erin Michelle Parry, Stephanie Deng, Nathan Dangle, Neil Ruthen, et al.. ZNF683 (Hobit) Marks a CD8+ T Cell Population Associated with Anti-Tumor Immunity Following Anti-PD-1 Therapy for Richter Syndrome. Blood, 2022, 140 (Supplement 1), pp.1807-1808. ⟨10.1182/blood-2022-162550⟩. ⟨hal-03950370⟩
30 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More